Well Lead Med Co Ltd (603309) - Net Assets
Based on the latest financial reports, Well Lead Med Co Ltd (603309) has net assets worth CN¥1.95 Billion CNY (≈ $284.94 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.91 Billion ≈ $425.49 Million USD) and total liabilities (CN¥960.53 Million ≈ $140.56 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 603309 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.95 Billion |
| % of Total Assets | 66.97% |
| Annual Growth Rate | 19.23% |
| 5-Year Change | 66.36% |
| 10-Year Change | 144.41% |
| Growth Volatility | 27.64 |
Well Lead Med Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Well Lead Med Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how large is Well Lead Med Co Ltd's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Well Lead Med Co Ltd (2011–2024)
The table below shows the annual net assets of Well Lead Med Co Ltd from 2011 to 2024. For live valuation and market cap data, see Well Lead Med Co Ltd (603309) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.90 Billion ≈ $278.48 Million |
+3.60% |
| 2023-12-31 | CN¥1.84 Billion ≈ $268.80 Million |
+5.58% |
| 2022-12-31 | CN¥1.74 Billion ≈ $254.58 Million |
+9.32% |
| 2021-12-31 | CN¥1.59 Billion ≈ $232.89 Million |
+39.12% |
| 2020-12-31 | CN¥1.14 Billion ≈ $167.40 Million |
+10.38% |
| 2019-12-31 | CN¥1.04 Billion ≈ $151.66 Million |
+10.25% |
| 2018-12-31 | CN¥940.07 Million ≈ $137.56 Million |
+4.44% |
| 2017-12-31 | CN¥900.07 Million ≈ $131.71 Million |
+4.26% |
| 2016-12-31 | CN¥863.31 Million ≈ $126.33 Million |
+10.87% |
| 2015-12-31 | CN¥778.65 Million ≈ $113.94 Million |
+110.34% |
| 2014-12-31 | CN¥370.18 Million ≈ $54.17 Million |
+22.43% |
| 2013-12-31 | CN¥302.37 Million ≈ $44.25 Million |
+21.25% |
| 2012-12-31 | CN¥249.37 Million ≈ $36.49 Million |
+28.94% |
| 2011-12-31 | CN¥193.41 Million ≈ $28.30 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Well Lead Med Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2741.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥828.53 Million | 43.95% |
| Common Stock | CN¥292.87 Million | 15.54% |
| Other Components | CN¥763.58 Million | 40.51% |
| Total Equity | CN¥1.88 Billion | 100.00% |
Well Lead Med Co Ltd Competitors by Market Cap
The table below lists competitors of Well Lead Med Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Inner Mongolia North Hauler Joint Stock Co Ltd
SHG:600262
|
$606.49 Million |
|
Fireweed Zinc Ltd
V:FWZ
|
$607.08 Million |
|
Qingdao Citymedia Co Ltd
SHG:600229
|
$607.16 Million |
|
Mitek Systems Inc
NASDAQ:MITK
|
$607.24 Million |
|
RaySearch Laboratories AB (publ)
ST:RAY-B
|
$606.23 Million |
|
Natural Grocers by Vitamin Cottage Inc
NYSE:NGVC
|
$606.22 Million |
|
Shinkong Textile Co Ltd
TW:1419
|
$606.20 Million |
|
Shandong Rike Chemical
SHE:300214
|
$606.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Well Lead Med Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,817,095,135 to 1,884,975,721, a change of 67,880,586 (3.7%).
- Net income of 219,393,029 contributed positively to equity growth.
- Dividend payments of 155,604,787 reduced retained earnings.
- Share repurchases of 1,969,428 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥219.39 Million | +11.64% |
| Dividends Paid | CN¥155.60 Million | -8.26% |
| Share Repurchases | CN¥1.97 Million | -0.1% |
| Other Changes | CN¥6.06 Million | +0.32% |
| Total Change | CN¥- | 3.74% |
Book Value vs Market Value Analysis
This analysis compares Well Lead Med Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.20x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 14.35x to 2.20x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.99 | CN¥14.20 | x |
| 2012-12-31 | CN¥1.27 | CN¥14.20 | x |
| 2013-12-31 | CN¥1.55 | CN¥14.20 | x |
| 2014-12-31 | CN¥1.89 | CN¥14.20 | x |
| 2015-12-31 | CN¥3.15 | CN¥14.20 | x |
| 2016-12-31 | CN¥3.33 | CN¥14.20 | x |
| 2017-12-31 | CN¥3.40 | CN¥14.20 | x |
| 2018-12-31 | CN¥3.60 | CN¥14.20 | x |
| 2019-12-31 | CN¥3.95 | CN¥14.20 | x |
| 2020-12-31 | CN¥4.36 | CN¥14.20 | x |
| 2021-12-31 | CN¥6.07 | CN¥14.20 | x |
| 2022-12-31 | CN¥5.95 | CN¥14.20 | x |
| 2023-12-31 | CN¥6.23 | CN¥14.20 | x |
| 2024-12-31 | CN¥6.44 | CN¥14.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Well Lead Med Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.64%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.54%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 1.51x
- Recent ROE (11.64%) is below the historical average (13.26%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 24.78% | 13.76% | 0.95x | 1.89x | CN¥28.58 Million |
| 2012 | 22.35% | 14.36% | 0.95x | 1.64x | CN¥30.73 Million |
| 2013 | 21.06% | 14.54% | 0.92x | 1.57x | CN¥33.39 Million |
| 2014 | 18.34% | 13.66% | 0.94x | 1.42x | CN¥30.85 Million |
| 2015 | 11.74% | 16.64% | 0.62x | 1.13x | CN¥13.50 Million |
| 2016 | 9.24% | 15.38% | 0.53x | 1.13x | CN¥-6.50 Million |
| 2017 | 7.24% | 10.25% | 0.62x | 1.13x | CN¥-24.64 Million |
| 2018 | 7.05% | 8.77% | 0.53x | 1.53x | CN¥-27.34 Million |
| 2019 | 11.79% | 12.19% | 0.68x | 1.42x | CN¥18.38 Million |
| 2020 | 13.50% | 13.54% | 0.76x | 1.31x | CN¥39.69 Million |
| 2021 | 6.72% | 9.48% | 0.52x | 1.35x | CN¥-51.75 Million |
| 2022 | 9.66% | 12.22% | 0.57x | 1.38x | CN¥-5.82 Million |
| 2023 | 10.59% | 14.03% | 0.53x | 1.43x | CN¥10.78 Million |
| 2024 | 11.64% | 14.54% | 0.53x | 1.51x | CN¥30.90 Million |
Industry Comparison
This section compares Well Lead Med Co Ltd's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,385,433,030
- Average return on equity (ROE) among peers: 2.87%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Well Lead Med Co Ltd (603309) | CN¥1.95 Billion | 24.78% | 0.49x | $606.48 Million |
| Beijing Centergate Technologies Holding Co Ltd (000931) | $1.79 Billion | 0.80% | 1.04x | $517.97 Million |
| Blue Sail Medical Co Ltd (002382) | $984.34 Million | 4.77% | 0.96x | $1.04 Billion |
| Andon Health Co Ltd (002432) | $608.95 Million | -24.76% | 0.35x | $5.18 Billion |
| Allmed Medical Products Co Ltd Class A (002950) | $3.13 Billion | 12.99% | 0.84x | $1.31 Billion |
| Guangzhou Improve Med Instrument (300030) | $963.72 Million | 1.16% | 0.81x | $382.31 Million |
| QITIAN Technology Group Co Ltd (300061) | $451.92 Million | 8.13% | 0.70x | $948.89 Million |
| Shanghai Tofflon Science Tech (300171) | $2.41 Billion | 11.06% | 0.57x | $1.49 Billion |
| Truking Technology Ltd (300358) | $2.39 Billion | 1.73% | 0.74x | $1.04 Billion |
| Jiangxi Sanxin Medtec Co Ltd (300453) | $552.62 Million | 6.63% | 0.13x | $810.58 Million |
| Shenyang Xingqi Pharmaceutical Co Ltd (300573) | $574.90 Million | 6.24% | 0.48x | $2.53 Billion |
About Well Lead Med Co Ltd
Well Lead Medical Co., Ltd. engages in the development, production, and sale of medical devices in urology, endourology, anaesthesia, respiratory, hemodialysis, and pain management areas worldwide. It provides urology products, including Foley catheter, Nelaton catheters, urine collection products, and accessories; endourology products, such as the ClearPetra family system, ureterorenoscope, guid… Read more